Abstract Details

Title Real-world Clinical and Safety Outcomes from a Prospective: Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients

Topic Movement Disorders

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 17-004

Objective To evaluate real-world clinical and safety outcomes of patients with Essential Tremor (ET) treated using a directional Deep Brain Stimulation (DBS) system with Multiple Independent Current Control (MICC).

Background ET has been reported to affect about 0.9% of the world population. DBS targeting the ventral intermediate nucleus (Vim) is the preferred surgical treatment for medication-refractory ET. MICC-enabled directional DBS systems may offer improved symptom control and programming flexibility. Real-world data are needed to validate these benefits across diverse clinical settings.

Design/Methods This ongoing, prospective, multicenter international registry (NCT04032470) includes up to 500 ET patients implanted with Boston Scientific Vercise DBS systems. Assessments include tremor severity (TETRAS), quality of life (QUEST), and Clinical Global Impression of Change (CGI). Safety data were collected via adverse event reporting.

Results Among 88 enrolled subjects, 73 were activated. Mean age was 66.3 years, and mean disease duration was 20.4 years. At 2 years post-DBS, patients reported a 46% reduction in tremor hours (mean increase of 7.5 hours/day without tremor, p<0.001). QUEST Summary Index improved by 23.4 points (p<0.001), exceeding the threshold for clinical significance. TETRAS scores showed a 41% improvement in tremor severity and 60% improvement in activities of daily living, sustained through 2 years. Over 95% of clinicians and 93% of patients reported symptom improvement at 6 months, sustained at 2 years. Data collection is on-going and updated results will be presented.

Conclusions Directional DBS with MICC demonstrates sustained symptom relief and quality-of-life improvements in ET patients. High satisfaction rates and consistent safety outcomes support its clinical utility. Preliminary registry data confirm that MICC-enabled directional DBS systems offer significant, durable benefits for ET patients in real-world settings. These findings support broader adoption of advanced DBS technologies.

Authors/Disclosures
Rajat Shivacharan PRESENTER	Dr. Shivacharan has received personal compensation for serving as an employee of Boston Scientific.
Guenther Deuschl, MD, FAAN (Dept. of Neurology, Christain-Albrechts Univ)	Dr. Deuschl has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Deuschl has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Boston Scientific Cavion Functional Neuromodulation. The institution of Dr. Deuschl has received research support from Medtronic. Dr. Deuschl has received publishing royalties from a publication relating to health care.
Rick Schuurman, MD, PhD	Prof. Schuurman has nothing to disclose.
Griet Loret, MD (UZ Gent, Dienst Neurologie)	Dr. Loret has nothing to disclose.
Norbert Kovacs	Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbott. Norbert Kovacs has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie.
Michael Barbe	No disclosure on file
Marta Blazquez Estrada	Marta Blazquez Estrada has nothing to disclose.
Frederil A. Clement, MD (AZ Delta)	Dr. Clement has nothing to disclose.
Jung-Il Lee, MD	Prof. Lee has nothing to disclose.
Serge Jaumà Classen (Bellvitge University Hospital)	Serge Jaumà Classen has nothing to disclose.
David Pedrosa (University Hospital Giessen and Marburg)	David Pedrosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AbbVie. David Pedrosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bial. David Pedrosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific Corp.. David Pedrosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. David Pedrosa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Desitin. David Pedrosa has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. The institution of David Pedrosa has received research support from Boston Scientific Corp..
Jens Volkmann, MD (University Hospital of Wuerzburg)	Jens Volkmann, MD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ceregate. Jens Volkmann, MD has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Newronika. Jens Volkmann, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Boston Scientific. Jens Volkmann, MD has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Jens Volkmann, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bial. Jens Volkmann, MD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbott. The institution of Jens Volkmann, MD has received research support from DFG. The institution of Jens Volkmann, MD has received research support from BMBF. The institution of Jens Volkmann, MD has received research support from Boston Scientific. The institution of Jens Volkmann, MD has received research support from Medtronic.
Ana Oliveira, MD (Hospital Vila Franca de Xira)	Dr. Oliveira has nothing to disclose.
Steffen Paschen	The institution of Steffen Paschen has received research support from Deutsche Forschungsgemeinschaft. The institution of Steffen Paschen has received research support from Parkinsonfonds. The institution of Steffen Paschen has received research support from UCB .
Edward Goldberg, MD	Dr. Goldberg has received personal compensation for serving as an employee of Boston Scientific .

��ɫ��

��ɫ��